Steven R. Altman joined the Dexcom Board of Directors in 2013. Up until his retirement from Qualcomm Incorporated in January 2014, Mr. Altman served as vice chairman of Qualcomm Incorporated and as a member of Qualcomm’s executive committee. In that role, Mr. Altman provided direction and guidance on key initiatives across all areas of the business, as well as on overall vision and strategy.
Mr. Altman joined Qualcomm in 1989 and was the chief architect of Qualcomm’s strategy for licensing its broad intellectual property portfolio for wireless communications, which has accelerated the growth of CDMA technology. In that role, he was responsible for structuring and negotiating Qualcomm’s license agreements, joint ventures and strategic relationships. Under Mr. Altman’s leadership, Qualcomm entered into domestic and international licensing agreements with the world's largest telecommunications and electronics companies.
Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ames & Frye (which later become DLA Piper), where he specialized in intellectual property, mergers and acquisitions, securities, and general corporate matters. He joined Qualcomm in 1989 as corporate counsel with responsibility for licensing and contracts, quickly moving up through the management ranks and becoming vice president and general counsel in 1992. He became general manager of QTL when that organization was formed in 1995; and senior vice president in 1996. In 1998, Mr. Altman was named executive vice president; and president of QTL in 2000. From 2005 to 2011, Mr. Altman served as the president of Qualcomm where his leadership and contributions helped enable Qualcomm’s successful growth, evolution and expansion.
Mr. Altman graduated from Northern Arizona University in 1983 with a bachelor’s degree in political science and administration; he received his Juris Doctor from the University of San Diego School of Law in 1986. Mr. Altman served as a board member of Ubiquiti Networks, Inc. from October 2013 to December 2015. He is also a member of the University of California at San Diego (UCSD) Health Board of Advisors, Mr. Altman also serves as a board member for privately-held companies ViaCyte Inc. and Brain Corporation. As a former board member of the Juvenile Diabetes Research Foundation (JDRF), he remains an active supporter of the JDRF and numerous other charitable causes.
What is Steven R. Altman's net worth?
The estimated net worth of Steven R. Altman is at least $3.96 million as of January 16th, 2024. Mr. Altman owns 53,132 shares of DexCom stock worth more than $3,956,209 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Altman may own. Learn More about Steven R. Altman's net worth.
How do I contact Steven R. Altman?
Has Steven R. Altman been buying or selling shares of DexCom?
Steven R. Altman has not been actively trading shares of DexCom during the past quarter. Most recently, Steven R. Altman sold 1,568 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $122.86, for a transaction totalling $192,644.48. Following the completion of the sale, the director now directly owns 53,132 shares of the company's stock, valued at $6,527,797.52. Learn More on Steven R. Altman's trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 9/9/2024.